相关实验视频
Updated: Jan 16, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
906
低剂量生长激素治疗对肥胖的影响:随机对照试验的元分析
Fei Sun1, Aili Yang1, Yuxin Jin1
1Department of Endocrinology, Tangdu Hospital, Fourth Military Medical University (Air Force Medical University), Xi'an, P.R. China.
Postgraduate medicine
|October 2, 2025
概括
低剂量复合人体生长激素 (rhGH) 疗法显著减少内脏脂肪,增加大腿肌肉在肥胖的成年人没有GH缺乏. 这种治疗显示出型肥胖症的潜力,没有报告严重不良事件.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 肥胖问题研究研究
背景情况:
- 众所周知,生长激素 (GH) 可以减少内脏脂肪并改善肥胖成人的身体组成.
- 高剂量GH疗法与不良影响有关,低剂量GH的安全性和有效性在非缺乏肥胖个体中尚不清楚.
- 这项研究解决了关于在没有GH缺乏症的肥胖人口中低剂量GH治疗的知识差距.
研究的目的:
- 为了评估低剂量重组人体生长激素 (rhGH) 对没有GH缺乏症的肥胖成年人身体组成的影响.
- 评估 rhGH 对脂质特征和葡萄糖代谢的影响.
- 确定与低剂量 rhGH 治疗相关的安全性和不良事件.
主要方法:
- 对随机对照试验 (RCT) 进行了系统审查和元分析,遵循PRISMA指南.
- 在PubMed,Cochrane图书馆和EMBASE数据库中进行了搜索,截至2024年12月.
- 包括RCT集中在没有GH缺乏症的肥胖个体上,检查与身体组成,脂质或葡萄糖代谢相关的结果.
主要成果:
- 分析了10个带有420名参与者的RCT,治疗持续时间从4周到72周.
- 低剂量的rhGH显著减少了内脏脂肪组织 (SMD: -0.34) 和增加了大腿肌肉面积 (MD: 6.33 cm2).
- 禁食葡萄糖水平略有增加 (MD:4.18 mg/dL),没有报告严重不良事件.
结论:
- 低剂量rhGH疗法有效地减少内脏脂肪,并增加肌肉质量在缺乏GH缺乏肥胖个体.
- 这些发现表明,对sarcopenic肥胖症有潜在的治疗益处.
- 建议通过更大规模的长期研究进行进一步的研究,以确认这些影响.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Nature and Nurture
22.2K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.2K
Hypoglycemia and Glucagon
835
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
835
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169

